Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Capricor Therapeutics (CAPR) Other Operating Expenses (2019 - 2025)

Capricor Therapeutics has reported Other Operating Expenses over the past 6 years, most recently at -$6846.0 for Q3 2025.

  • Quarterly results put Other Operating Expenses at -$6846.0 for Q3 2025, up 99.4% from a year ago — trailing twelve months through Dec 2025 was -$157519.0 (up 86.2% YoY), and the annual figure for FY2025 was -$157519.0, down 39.64%.
  • Other Operating Expenses for Q3 2025 was -$6846.0 at Capricor Therapeutics, up from -$150673.0 in the prior quarter.
  • Over the last five years, Other Operating Expenses for CAPR hit a ceiling of $17389.0 in Q2 2023 and a floor of -$1.1 million in Q3 2024.
  • Median Other Operating Expenses over the past 5 years was -$5388.0 (2023), compared with a mean of -$103233.8.
  • Biggest five-year swings in Other Operating Expenses: surged 149.81% in 2023 and later plummeted 20917.15% in 2024.
  • Capricor Therapeutics' Other Operating Expenses stood at $13915.0 in 2021, then tumbled by 346.25% to -$34266.0 in 2022, then soared by 98.09% to -$653.0 in 2023, then crashed by 1990.2% to -$13649.0 in 2024, then surged by 49.84% to -$6846.0 in 2025.
  • The last three reported values for Other Operating Expenses were -$6846.0 (Q3 2025), -$150673.0 (Q1 2025), and -$13649.0 (Q4 2024) per Business Quant data.